Physician profile
Sarah M Bair
NPI 1760670863
$2,061.98
in general payments reported to CMS, 2019-2025
17 companies · $85.62 in 2025
The $85.62 reported for 2025 was less than what a typical Dermatopathology (Dermatology) provider received nationally (typical 2025 total: $251).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $386 · 2020: $186 · 2021: $33.37 · 2022: $1,159 · 2023: $167 · 2024: $44.32 · 2025: $85.62.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $297.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $296.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $986.97 | 2019-2022 | |
| Pfizer INC. | $169.14 | 2019-2023 | |
| Leo Pharma INC. | $165.03 | 2022-2024 | Adbry |
| Novartis Pharmaceuticals Corporation | $125.57 | 2019-2025 | |
| Abbvie INC. | $117.44 | 2019-2020 | |
| Galderma Laboratories, L.P. | $104.74 | 2019-2021 | |
| Genzyme Corporation | $88.86 | 2019-2025 | |
| Amgen INC. | $74.84 | 2020-2024 | Otezla |
| Sun Pharmaceutical Industries INC. | $50.26 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $46.98 | 2019 | |
| Janssen Biotech, INC. | $31.30 | 2019 | |
| Incyte Corporation | $19.72 | 2022 | |
| Ucb, INC. | $19.51 | 2025 | Bimzelx |
| Lilly USA, LLC | $17.71 | 2024 | Taltz |
| Journey Medical Corporation | $16.84 | 2025 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vyne Pharmaceuticals INC. | $15.31 | 2021 | |
| Organon LLC | $11.76 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Bair listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.